Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Gastric01: rilvegostomig + fluoropyrimidine + trastuzumab deruxtecan versus trastuzumab + chemotherapy + pembrolizumab in first-line HER2-positive gastric cancer
CTR20250520Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rilvegostomig, trastuzumab deruxtecan, trastuzumab, pembrolizumab, fluorouracil and 3 more in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2026; status: active.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20250520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250520.